KPC Cell Line (C57/BL6 genetic background)

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: KPC Cell Line (C57/BL6 genetic background)
• Alternate name: PDAC cell line
• Cancer: Pancreatic cancer
• Cancers detailed: Pancreatic cancer ; Pancreatic ductal adenocarcinoma
• Research fields: Cancer;Drug development
• Tool sub type: Continuous
• Organism: Mouse
• Gender: Male
• Disease: Cancer
• Growth properties: Loosely adherent
• Model: Transgenic
• Conditional: No
• Description: This KPC cell line represents a useful model of pancreatic ductal adenocarcinoma. This cell line was established from a popular KPC mouse model (Hingorani et al. 2005). It is applicable for use with C57BL/6 mice. Details on source mouse model The KPC mice from which the KPC cell is derived, are an establish clinically relevant model of PDA, that develop many of the key features of observed in human PDA such as pancreatic intraepithelial neoplasia. The KPC mouse contains a conditional point mutation in the transformation related protein 53 gene (TP53R172H), and a point mutation in the KRAS gene (KRASG12D) both of which generate non-functional proteins. A lox-stop-lox termination sequence is encoded upstream of both mutated genes to prevent expression in the absence of Cre recombinase. PDX1 (pancreatic and duodenal homeobox 1) is a transcription factor necessary for pancreatic development. The PDX1 promoter enables expression of Cre recombinase in acini, islet and duct cells of the pancreas. Cre-mediated recombination excises the two lox-stop-lox termination sequences and enables expression of both oncogenes: KRASG12D and TP53R172H in pancreatic tissue. Tissues not expressing Cre recombinase remain functionally heterozygous of the KRAS and TRP53 loci. KPC cell line The KPC cell line was derived from a KPC model that has been backcrossed for 10 generations into C57/B6 genetic background. This cell line retains the mutations seen in the parental KPC murine model. This cell line has been used in orthotropic injections into C57BL/6 mice, generating models of PDA. This KPC model can be used for PDA modelling, biomarkers investigation, genetics, and metastasis studies as well as drug discovery and development. Our current stock of this model is derived from male mice.
• Application: PDA modeling, biomarkers investigation, genetics and metastasis studies, drug discovery and development
• Production details: These cells are from the KPC mouse which has been backcrossed to F10 in C57/BL6. KPC Subtype: C57Bl6/J. Isolation of the cells: For each cell line, a 5mm diameter piece of tissue was harvested from solid PDAC arising in a C57BL/6 KPC mouse into DMEM. The tissue was chopped into a fine paste, resuspended in DMEM + L-Glut, Pen-Strep and 20% FBS, and plated out in a 25cm flask. The medium was changed after 2 days. Once confluent the cells were passaged as normal and grown in DMEM + L-Glut, Pen-Strep and 10% FBS in normoxic conditions at 37C in a humidified incubator
• Biosafety level: 1

Target Details

• Target: TP53, KRAS

Applications

• Application: PDA modeling, biomarkers investigation, genetics and metastasis studies, drug discovery and development

Handling

• Format: Frozen
• Growth medium: DMEM containing 10% foetal bovine serum and 2 mM l-glutamine
• Temperature: 37 ° C
• Atmosphere: CO2
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice
• Storage conditions: Liquid Nitrogen
• Subculture routine: Cells are loosely adherent but will need trypsinising. DMEM containing 10% foetal bovine serum and 2 mM l-glutamine with 5% CO2 and air. A 1:2 split can be made every two days which is relatively standard. Incubated as standard
• Mycoplasma free: Yes

Related Tools

• Related tools: KPC Cell Line (mixed genetic background)

References

• Sebastiano et al. 2020. Sci. Adv. 6. PMID: 33127675
• Li et al. 2014. Gastroenterology. 146(5):1386-96.e1-17. PMID: 24462734
• Hingorani et al. 2005. Cancer Cell. 7(5):469-83. PMID: 15894267

Documentation

• Product Datasheet